Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexMale
Age18+
SponsorMayo Clinic

About this trial

This early phase I is to find out how common vitamin D insufficiency is among African American patients with a history of prostate cancer that has not spread to other parts of the body (localized) or has spread to other places in the body (metastatic) and how vitamin D insufficiency affects the immune system. This study also aims to find out if replacing vitamin D results in normalization of the immune function. Information from this study may benefit prostate cancer patients by identifying vitamin D insufficiency which in several studies had been found to contribute to more aggressive prostate cancers.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

African American males, age >= 18 years

Patients with a previous history of localized or metastatic or locally recurrent prostate cancer

Patients with Vitamin D levels below 30 ng/ml

Disqualifiers

Known hypersensitivity to vitamin D

End stage renal failure on dialysis

Liver cirrhosis

Currently taking a vitamin D or multivitamin supplement, that has more than 400 IU/10mcg of vitamin D daily for the past month

Trial design

Design model

Single group

Treatments tested in this trial

  • Cholecalciferol

    Dietary supplement

    Given PO

  • Quality-of-Life Assessment

    Other intervention

    Ancillary studies

  • Biospecimen Collection

    Procedure/Surgery

    Undergo blood sample collection

Treatment groups

220 Participants
are divided into 1 treatment group
Group A: Treatment (cholecalciferol)Experimental treatment 3 interventions

Trial outcomes

Primary outcomes

1

Change in circulating immunological cell function

Participants will have blood drawn to measure serum levels of 25-hydroxyvitamin D (25OHD) and to determine immune response. Laboratory endpoints for the levels of antigen-specific T cells and antibodies before and after vitamin D supplementation will be compared. A participant will be considered to have responded if they have developed a ≥3-fold increase in antigen-specific T cells or antibodies at 8 weeks. If T-cell immunity is undetectable, a positive response will be defined as ≥50 antigen-specific T cells/million PBMCs.

Time frame
Baseline; 8 weeks

Secondary outcomes

1

Prevalence of vitamin D insufficiency

Participants will have blood drawn to measure serum levels of 25OHD. The mean and median 25OHD level will be estimated, as well as the percentage of participants that have low vitamin D levels (\<30 ng/mL).

Time frame
Baseline; 8 weeks
2

Differences in the peripheral blood immunological cell function

Levels of antigen-specific T cells and antibodies before and after vitamin D supplementation will be compared between black/AA patients with metastatic or locally recurrent prostate cancer and those with localized prostate cancer

Time frame
Baseline; 8 weeks
3

Vitamin D replacement association with PSA progression free survival (PSA-PFS)

Participants with detectable changes in immune response will be compared to those with no detectable changes in immune response and compared to stage-matched historical controls to determine whether vitamin D replacement is associated with improvement in PFA-PFS.

Time frame
Up to 3 years

Other outcomes

1

Change in Quality of Life

Assessed by the Human Services' Centers for Disease Control and Prevention (CDC) Health-Related Quality of Life (HRQOL) Healthy Days Questionnaire. The questionnaire consists of 144 questions about an individual's self-rated general health over the past 30 days. Questions ask about the number of days for which mental and physical health was not good (# of days, none, or don't know/not sure) and whether poor mental or physical health days affected usual activities (yes, no, or don't know/not sure). A higher score (more healthy days) reflects better physical and mental well-being, while a lower score (more unhealthy days) indicates a greater impact from poor physical or mental health and activity limitations.

Time frame
Baseline; 8 weeks
2

Difference in peripheral blood immunological cell function by population

A similar parallel study is being conducted at the University of Ilorin in Ilorin, Nigeria. Immunological results from the study at Mayo Clinic will be compared retrospectively with the results from the study in Nigeria under a separate study protocol.

Time frame
Up to 3 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Mayo Clinic

Lead sponsor

Congressionally Directed Medical Research Programs

Collaborator